Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevas nanovesículas no liposomadas y su uso en la administración de ácido nucleico

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20190729002
Publicado:
30/09/2019
Caducidad:
30/09/2020
Resumen:
Un centro español de investigación biomédica ha desarrollado nuevas nanovesículas no liposomadas (QS), una nueva herramienta de administración de ácido nucleico que permite que el ácido nucleico transportado desempeñe su actividad en el citosol y pueda emplearse para el tratamiento del cáncer. Las nanovesículas están compuestas por conservantes y derivados de esterol, aprobados por la FDA (Administración de Alimentos y Medicamentos de los Estados Unidos) y EMA (Agencia Europea de Medicamentos). Estas nanovesículas presentan una gran eficiencia de transfección in vitro, buena biocompatibilidad, comparable a la de otros reactivos de transfección comerciales (por ejemplo, Lipofectamine® 2000), y una potente actividad antitumoral en líneas celulares de neuroblastoma. El centro de investigación busca socios con el fin de establecer acuerdos de licencia, cooperación en materia de investigación o cooperación técnica.

Details

Tittle:
Novel engineered non-liposomal nanovesicles and their use in nucleic acid delivery
Summary:
A Spanish biomedical research networking center has developed novel engineered non-liposomal nanovesicles, here named QS, an innovative tool for nucleic acid delivery, allowing the transported nucleic acid to perform its activity in the cytosol, and to be used for the treatment of cancer, looking to establish license, research cooperation or technical cooperation agreements.
Description:
This research networking center gathers some of the main Spanish research groups in biomedicine, located in more than 100 institutions as universities, hospitals and technological centers distributed around the country.

RNA therapeutics is an emerging field with a promising number of targets around all the transcriptome, which includes small RNAs like small interfering RNA (siRNA), microRNA (miRNA), among others. Although, the RNA based-therapies may be an alternative to chemoresistant tumors, the in vivo administration is still a challenge in the field, due to the rapid clearance and degradation of small RNAs in the bloodstream.

As of today, nanomedicine promises the precise delivery of drugs to disease sites (i.e. tumours) with reduced off-target toxicities. Liposomal nanovesicles are one of the most promising candidates for drug delivery in nanomedicine. However, these liposomal-based medicinal products still present unsolved drawbacks such as poor colloidal stability, short half-life when administered in the blood circulation, nonspecific bio-distribution and modification of endogenous RNA machinery.

Novel engineered non-liposomal nanovesicles (QS) have been developed to overcome some of the previously stated problems related to application of RNA based therapeutics in the treatment of human diseases, such as cancer.
Advantages and Innovations:
The new QS is an innovative tool for nucleic acid delivery, allowing the transported nucleic acid to perform its activity inside the cell (cytosol). QS may be used in the development of RNA (Ribonucleic acid) based therapeutics for the treatment of human diseases, such as cancer.
The engineered QS are composed by preservatives and sterol derivates, all elements FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) approved.
These QS have shown great in vitro transfection efficiencies and good biocompatibility, comparable to other commercial transfection reagents (e.g. Lipofectamine® 2000) and also potent anti-tumoural activity in neuroblastoma cell lines.
Development of a pharmaceutical composition comprising a therapeutically effective amount of the nanovesicle and a pharmaceutically acceptable excipient or vehicle can be carried out.
The nanovesicle or the pharmaceutical composition can be used as a medicament for the treatment of diseases that use nucleic acids as therapeutic agent (e.g. cancer, in neuroblastoma)
These QS can be also used as a bioimaging and theranostic tool.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Priority European patent application filed.
Suitable for International extension (PCT application).

Partner sought

Type and Role of Partner Sought:
Patent ready for licensing-out.
The research center is seeking industrial partners, either from the Biotech or Pharma sectors, to:
- enter into preclinical R-Y-D collaboration (in vitro and/or in vivo drug testing) through research cooperation agreements.
- Further development until clinical proof-of-concept via license or technical cooperation agreements.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001024 Biomateriales médicos
06006006 Nanomateriales biológicos
03004007 Pharmaceutics
06001015 Productos farmacéuticos / medicamentos